Press Releases

Date Title and Summary View
Jan 17, 2019
Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
32.7% Objective response rate in HER2+ IHC 3+ second-line gastric cancer patients Well tolerated in dose escalation and expansion cohorts ROCKVILLE, MD , Jan. 17, 2019 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and
Jan 07, 2019
MacroGenics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Rockville, MD , Jan. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig , M.D., Ph.D.,
Dec 07, 2018
MacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies
ROCKVILLE, MD , Dec. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on December 6 , it received a
Dec 03, 2018
Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting
Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patients Translational studies suggest potential strategy for biomarker-based patient selection ROCKVILLE, Md. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Nov 29, 2018
MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing development Expand Zai Lab’s late-stage clinical pipeline with margetuximab and obtain rights to first-in-class dual checkpoint inhibitor, MGD013 Jointly conduct global studies across multiple
Nov 27, 2018
MacroGenics Announces Participation in Three Investor Conferences
ROCKVILLE, MD , Nov. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 14, 2018
MacroGenics Announces Poster Presentation on Preclinical PD-L1 x CD137 DART® Program at the EORTC-NCI-AACR Symposium in Dublin
ROCKVILLE, MD , Nov. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it had presented a poster titled
Nov 09, 2018
MacroGenics Reports Presentation of Clinical Data at 33rd Annual SITC Meeting
Enoblituzumab + pembrolizumab combination study data reported: ORRs in anti-PD-1/PD-L1 naïve SCCHN and NSCLC cohorts benchmarked favorably vs. approved anti-PD-1 agents Interim data from Phase 1 dose expansion study of MGA012 (anti-PD-1): objective responses in NSCLC, cervical cancer, endometrial
Nov 07, 2018
MacroGenics Provides Update on Corporate Progress and 3rd Quarter 2018 Financial Results
Margetuximab: Phase 3 SOPHIA study enrollment completed; topline results 1Q 2019 PD-1 franchise: MGD013 cohort expansions initiated; $15 million in MGA012 milestones triggered; MGD019 IND cleared B7-H3 franchise: enoblituzumab oral presentation at SITC ; MGC018 Phase 1 study initiating
Oct 31, 2018
MacroGenics Announces Date of Third Quarter 2018 Financial Results Conference Call
Rockville, MD , Oct. 31, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 7, 2018 , the Company will release its financial results for the quarter ended September 30, 2018 . The Company's management team will host a conference call discussing the
Oct 22, 2018
MacroGenics Announces Participation in Three Investor Conferences
ROCKVILLE, MD , Oct. 22, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Sep 26, 2018
MacroGenics Announces Participation in Two Upcoming Investor Conferences
ROCKVILLE, MD , Sept. 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 30, 2018
MacroGenics Announces Participation in Three Upcoming Investor Conferences

Rockville, MD , Aug. 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Aug 09, 2018
MacroGenics to Present at Wedbush PacGrow Healthcare Conference

ROCKVILLE, MD , Aug. 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Aug 07, 2018
MacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results

ROCKVILLE, Md. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and

Jul 30, 2018
MacroGenics Announces Date of Second Quarter 2018 Financial Results Conference Call

ROCKVILLE, MD , July 30, 2018 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, August 7, 2018 , the Company will release its financial results for the quarter ended June 30, 2018 . The Company's management team will host a conference call discussing the

Jun 05, 2018
MacroGenics to Present at Jefferies Global Healthcare Conference

ROCKVILLE, MD , June 05, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

May 07, 2018
MacroGenics to Present at Deutsche Bank Health Care Conference

ROCKVILLE, MD , May 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

May 07, 2018
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results

ROCKVILLE, Md. , May 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress update and reported

Apr 30, 2018
MacroGenics Announces Date of First Quarter 2018 Financial Results Conference Call

ROCKVILLE, MD , April 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Monday, May 7, 2018 , the Company will release its financial results for the quarter ended March 31, 2018 . The Company's management team will host a conference call discussing the Company's

Apr 02, 2018
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ROCKVILLE, MD , April 02, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the closing of its previously

Mar 28, 2018
MacroGenics Announces Pricing of Public Offering of Common Stock

ROCKVILLE, MD , March 28, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public

Mar 26, 2018
MacroGenics Announces Proposed Public Offering of Common Stock

ROCKVILLE, MD , March 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten

Mar 09, 2018
MacroGenics to Present at Cowen Health Care Conference
Rockville, MD, March 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Additional Formats
Feb 27, 2018
MacroGenics Provides Update on Corporate Progress and 2017 Financial Results
ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress update and reported
Additional Formats